A dual-transformable MgGa-MOF nanoplatform for HCC therapy via lactate metabolism blockade and immune reactivation
Open Access
- 5 April 2026
- journal article
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 24 (1)
Abstract
Microwave ablation (MWA) has emerged as one of the preferred modalities for treating hepatocellular carcinoma (HCC). However, its therapeutic efficiency is restricted by lactate accumulation after MWA. Lactate serves as a metabolic fuel for residual tumor cells, as well as acidifies the tumor microenvironment (TME) and impairs immune function, thereby fostering tumor recurrence and metastatic dissemination. Herein, we designed a dual-transformation strategy that turns metabolic fuel into metabolic burden and immunosuppressive pressure into power, implemented via bimetallic MOF-based nanoplatform (Dis@MgGa-MOF@TD/FA, DMGTF NCs), to counteract microwave-induced lactate elevation, reactivate immune activity and suppress primary tumor growth and metastatic progression. Specifically, after intravenous administration, folic acid (FA)-modified DMGTF accumulates in HCC, where microwave irradiation opens the 1-Tetradecanol (TD) gate to release diclofenac sodium (Dis). The released Dis suppresses MCT4-mediated lactate efflux, thereby disrupting lactate-driven energy supply and reshaping the TME. Meanwhile, microwave-activated DMGTF generates abundant ROS to impair mitochondrial lactate oxidation, thereby promoting intracellular lactate accumulation and inducing metabolic stress. Moreover, framework-derived Mg²⁺ restarts T cells, boosts proliferation, and augments IFN-γ secretion, converting immunosuppressive "pressure" into antitumor "power". As a result, DMGTF NCs combined with MW achieve excellent therapeutic effects in a model of hepatocellular carcinoma and lung metastasis. This MOF-based dual-transformation strategy provides a promising solution to the long-standing challenge of post-MWA tumor relapse and dissemination, offering new insights into the effective control of liver cancer.Keywords
All Related Versions
Funding Information
- Fundamental Research Program of Shanxi Province (202403021221305)
- the Science and Education Cultivation Fund of the National Cancer and Regional Medical center of Shanxi Provincial Cancer hospital (QH2023013)
- the Science and Education Cultivation Fund of the National Cancer and Regional Medical center of Shanxi Provincial Cancer hospital (TD2023003, BD2023004)
- National Natural Science Foundation of China (82172048, U21A20378)
- The Science and Technology Cooperation and Exchange Special Project of Shanxi Province (202304041101030)
This publication has 55 references indexed in Scilit:
- Nanoengineering‐Based Strategies for Enhancing Dynamic TherapySmall, 2026
- Innovative PDK1‐Degrading PROTACs Transform Cancer Aerobic Glycolysis and Induce Immunogenic Cell Death in Breast CancerExploration, 2025
- Biomimetic MOF‐Based Nano‐Immunoactivator via Disruption of Ion Homeostasis for Strengthened Tumor Microwave‐ImmunotherapyAdvanced Functional Materials, 2024
- Prepared MW‐Immunosensitizers Precisely Release NO to Downregulate HIF‐1α Expression and Enhance Immunogenic Cell DeathSmall, 2023
- Lenvatinib delivery using a Gd/Fe bimetallic MOF: Enhancing antitumor immunity following microwave-based thermal therapyActa Biomaterialia, 2023
- Gallium containing bioactive materials: A review of anticancer, antibacterial, and osteogenic propertiesBioactive Materials, 2022
- Microwave ablation for hepatic malignancies: a systematic review of the technology and differences in devicesSurgical Endoscopy, 2022
- Heat shock protein A12A activates migration of hepatocellular carcinoma cells in a monocarboxylate transporter 4–dependent mannerCell Stress and Chaperones, 2022
- Downregulation of MCT4 for lactate exchange promotes the cytotoxicity of NK cells in breast carcinomaCancer Medicine, 2018
- Metal–Organic Framework (MOF)‐Based Drug/Cargo Delivery and Cancer TherapyAdvanced Materials, 2017